Nura raises $73.8M to target ALS through a unique target
Biospace reports that Nura Bio has raised $73.8 million in financing to carry two neuroprotective drug candidates through early to mid-stage clinical studies, including one to target ALS. Marc Freeman, Ph.D., is the company’s academic co-founder who conducted preclinical research that found the SARM1 protein played a role in axon degeneration in fly and mamm
